No new differences in safety and efficacy of BEL 200 mg SC plus SoC were seen in this 6-month OLE study compared with the DB phase. Objectives: To study B-cell subpopulation dynamics in SLE patients following Rituximab (RTX) therapy. Methods: The study included 31 SLE pts (3m/28f) with high (SLEDAI2K≥10-28 pts.) and moderate (SLEDAI2K<10-3 pts.) disease activity; out of them 12 pts with
Triple positivity was defined as positive antibodies against cardiolipin and β2GPI and a positive test for lupus anticoagulant. Results: 32 pts had high or medium level of aPL (anticardiolipin antibodies IgG,IgM, anti-β2glycoprotein antibodies IgG,IgM), 6 had low or normal level of aPL. 12 pts were triple positive. APPT and thrombin time before inclusion to trial were 44,2 [36,5;53,5] and 16,1 [14,9;17,0] , on 24 week after dabigatran etexilate start 51,0 [40,5;65,7] and 163,5 [108,7;240,0] and on 48 week 58,7 [45,6;63,2] and 194,1 [152,6;255,2] respectively.1 patient was excluded due to non-compliance. During follow-up period from 1,5 to 12 (10,6±3,2) months 7 pts (22,6%, 20,7 per 100 patient-years) experienced reccurent thrombosis including superficial vein thrombosis (n=2; 6,5%, 5,9 per 100 patient-years), thrombosis of paranephric veins (n=1; 3,2%, 2,9 per 100 patient-years), acute cerebrovascular disorders (n=4; 12,9%, 11,8 per 100 patient-years). All pts with reccurent thrombosis had high or medium level of aPL; 2/7 were triple positive, both had acute cerebrovascular disorders. 5 pts (16,1%, 14,8 
Results:
Overall, 677 patients completed the DB phase, 662 entered the OLE; 625 completed. Mean baseline Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index scores were 10.4 (BEL group) and 5.8 (PBO to BEL group, implying better SoC in the DB phase); Systemic Lupus International Collaborating Clinics/ACR Damage Index scores were similar (0.7 and 0.6, respectively). Most OLE AEs were mild/moderate in severity. Despite differences in BEL exposure (BEL: 1 year [DB]; 6-month OLE, and PBO to BEL: 6-month OLE), OLE AE rates were similar (table). Infections and infestations were the most frequent AEs (190/662, 28.7%; 55/662, 8.3%; serious AEs [SAEs] ; 17/662, 2.6%). AEs of depression/suicide/selfinjury (12/662, 1.8%), infections of special interest (17/662, 2.6%), post-injection systemic reactions (21/662, 3.2%) and local injection site reactions (4/662, 0.6%), were low. Two deaths occurred (metabolic acidosis; pneumonia and acute respiratory failure); unrelated to study drug. The percentage of patients worsening (≥2 grade) from baseline was low for all clinical laboratory parameters. Three patients had anti-BEL immune responses during the OLE or follow-up; this resolved on subsequent testing. Efficacy was maintained across the OLE. 
